TY - JOUR T1 - Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial JF - Hepatology Y1 - 2006 A1 - G.T. Everson A1 - Hoefs, J.C. A1 - Seeff, L.B. A1 - Bonkovsky, H.L. A1 - Naishadham, D. A1 - Shiffman, M.L. A1 - Kahn, J.A. A1 - Lok, A.S. A1 - A M Di Bisceglie A1 - Lee, W.M. A1 - Dienstag, J.L. A1 - Ghany, M.G. A1 - Morishima, C. A1 - HALT-C trial group KW - adverse effects KW - Antiviral Agents KW - Biopsy KW - Colorado KW - Disease KW - drug therapy KW - Drug Therapy,Combination KW - Female KW - Fibrosis KW - Gastroenterology KW - Genotype KW - HCV KW - hepatitis KW - Hepatitis C KW - Hepatitis C,Chronic KW - Humans KW - interferon KW - Interferon Alfa-2a KW - Interferon-alpha KW - Liver KW - Liver Cirrhosis KW - Male KW - Medicine KW - Middle Aged KW - Multicenter Studies KW - pathology KW - Patients KW - peginterferon KW - Platelet Count KW - Polyethylene Glycols KW - Proteins KW - Recombinant Proteins KW - Research KW - Research Support KW - Retreatment KW - Ribavirin KW - strategies KW - sustained virologic response KW - SVR KW - therapeutic use KW - therapy KW - treatment KW - Treatment Failure KW - Treatment Outcome VL - 44 SP - 1675-1684 IS - 6 ER -